File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial
Title | Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial |
---|---|
Authors | |
Issue Date | 20-Jul-2023 |
Persistent Identifier | http://hdl.handle.net/10722/336572 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Philip Hei | - |
dc.date.accessioned | 2024-02-16T10:31:44Z | - |
dc.date.available | 2024-02-16T10:31:44Z | - |
dc.date.issued | 2023-07-20 | - |
dc.identifier.uri | http://hdl.handle.net/10722/336572 | - |
dc.language | eng | - |
dc.relation.ispartof | US HAEA National Summit (20/07/2023-23/07/2023, , , Florida) | - |
dc.title | Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial | - |
dc.type | Conference_Paper | - |